Azathioprine-induced carcinogenesis in mice according to Msh2 genotype

Abstract

Insights

Azathioprine treatment accelerates cancer in mice with reduced DNA mismatch repair gene Msh2. Carcinogenesis risk depends on the number of functional Msh2 gene copies, impacting tumor development and survival.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Azathioprine, a thiopurine prodrug, is widely used in cancer therapy.
  • Exposure to azathioprine can lead to the selection of DNA mismatch repair-deficient cell clones.
  • Thiopurine drugs may increase the risk of neoplasms with microsatellite instability (MSI) due to deficient DNA mismatch repair.

Purpose of the Study:

  • To investigate the role of the DNA mismatch repair gene Msh2 in azathioprine-induced carcinogenesis.
  • To evaluate the impact of Msh2 gene status on tumor development and survival in mice treated with azathioprine.

Main Methods:

  • Azathioprine administration to Msh2-deficient, heterozygous, and wild-type mice.
  • Evaluation of tumorigenesis and survival using Kaplan-Meier curves and statistical tests.
  • Tumor sample characterization including histology, immunophenotyping, MSI analysis, and Msh2 status assessment.

Main Results:

  • Azathioprine-treated Msh2-heterozygous mice developed lymphomas with MSI and reduced survival.
  • Azathioprine-treated wild-type mice showed microscopic splenic lymphoid cell foci but no overt tumors or MSI.
  • Mice lacking Msh2 (Msh2-null) exhibited reduced lifespan and developed lymphomas with MSI, irrespective of azathioprine treatment.

Conclusions:

  • Azathioprine-induced carcinogenesis in mice is dependent on the number of functional Msh2 gene copies.
  • The Msh2 gene status significantly influences the susceptibility to azathioprine-driven tumor development.

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Mismatch Repair01:36

Mismatch Repair

Overview
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...